Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
In a young woman with large invasive breast carcinoma (case: pT3, lobular) s/p skin sparing mastectomy with positive anterior margin, what is the practical role for re-excision with or without PMRT?
For a young female (<40) with HR-/HER2+ cT1-2N1, ypT1aN0 s/p mastectomy with SLNB, would you offer PMRT?
How would you approach radiation for an elderly patient with pT2N1 TNBC s/p MRM and ALND who refused chemo-immunotherapy?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
In what circumstances would you offer axillary re-irradiation after salvage axillary dissection?
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
How do you choose between ALND and RNI in the setting of LYMPHA or S-Lympha surgery?
How do you advise patients on cardiotoxicity when they are expected to receive a low mean heart dose and low cardiac substructure doses with their radiation plan?
With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
